Map Pharmaceuticals Starts Phase IIa Study for Asthma Drug
Posted on: Thursday, 1 November 2007, 06:00 CDT
Map Pharmaceuticals has initiated a Phase IIa clinical trial evaluating its investigational candidate for the potential treatment of asthma and chronic obstructive pulmonary disease.
The drug, MAP0005, is a combination of a corticosteroid and a long-acting beta2-agonist delivered to the respiratory tract using MAP Pharmaceuticals' Tempo inhaler.
The primary endpoints of the trial are the change in forced expiratory volume in one second (FEV1) from baseline, the time to maximum change in FEV1 and the plasma levels for the inhaled corticosteroid.
The Phase IIa clinical trial is a randomized, open-label, active-controlled, crossover, safety and dose response study investigating the pharmacokinetics and pharmacodynamics of MAP0005 in approximately 18 adult asthmatic patients. The trial compares two different doses of MAP0005 with one dose of a commercially marketed combination product, all administered by inhalation.
Map Pharmaceuticals believes that by combining drugs at the micron or submicron particle level, rather than as separate particles, as practiced with current inhaled combination therapies, the synergistic effect of the drugs can be enhanced leading to increased dosing efficiency and consistency.
Source: Datamonitor
Related Articles
- Sonus Pharmaceuticals and OncoGenex Technologies Complete Business Combination; OncoGenex Pharmaceuticals to Commence Trading on NASDAQ Capital Market Today
- The Cost Of Running Trials Approaches 30% Of Pharmaceutical Companies' Entire Drug Development Budgets, However 75% Of Patient Studies Fail To Make Their Timelines
- Seattle Genetics Announces Initiation of SGN-40 Phase Ib Clinical Trial in Combination With Velcade for Multiple Myeloma
- MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
- Seattle Genetics Initiates SGN-33 Clinical Trial in Combination With Revlimid(R) for Myelodysplastic Syndromes (MDS)
- Seattle Genetics Earns Milestone Payment From Initiation of SGN-40 Phase Ib Clinical Trial in Combination With Rituxan for Non-Hodgkin Lymphoma
- Seattle Genetics Initiates SGN-40 Phase IIb Clinical Trial in Combination With Rituxan and Chemotherapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- Seattle Genetics Initiates SGN-40 Clinical Trial in Combination With Revlimid for Multiple Myeloma
- MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients With Asthma
- Google Maps Combines With Google Local
 |
 |
User Comments (0)
RSS Feeds